Drugs / VOPIKITUG
VOPIKITUG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04642365 | Jan 2021 → Jan 2024 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04158583 | Dec 2019 → Jul 2022 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VOPIKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650512 ↗ |
| Known as | RG-6292 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650512 ↗ |
| Known as | RO7296682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04642365 ↗ |
| Known as | TSK-031044GLY | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650512 ↗ |
| Action | Deplete | “T-Regulatory Cell Depleting Antibody” NCT04158583 ↗ |
| Modality | Monoclonal antibody | “A CD25-Targeting, T-Regulatory Cell Depleting Antibody” NCT04158583 ↗ |
| Route | Intravenous | “RO7296682 was administered by IV infusion Q3W.” NCT04158583 ↗ |